Lumipulse® G pTau 181 CSF
Immunoreaction cartridges for use with the LUMIPULSE G Analyzer for the quantitative measurement of Tau phosphorylated at threonine 181 (pTau 181) in human cerebrospinal fluid (CSF).
This CSF biomarker is intended to be used as an aid for diagnosis in patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.
The CSF biomarker supports the probability of AD pathology only as an adjunct to other diagnostic evaluations.
This product is For Research Use Only (RUO), not for use in diagnostic procedures.
Product # 231654
Product # 231661
Product # 231678
-
Documentation
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all product documentation right away.
Get access to this section and more
Create your free e-services account and get access to all our extra documentation (certificates, data sheets, ...), FAQs, ...
- Find & download CoA, SDS and CE declarations of conformity
- See all event dates where our products are presented
- Unlimited acces to our free e-learning videos
-
Insights
Mar 7, 2023Video - A Neurochemist's Search to Save Memories - Christa's and Charlotte's Story About Alzheimer's Disease
Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, who was diagnosed with Alzheimer's disease in...
Nov 29, 2022Scientific Poster - In an Optimized CSF Collection Protocol the pTau181/Aβ1-42 Ratio Increases Preanalytical Variability Over Measuring Aβ1-42 Alone
Background
Core cerebrospinal fluid (CSF) biomarker concentrations for β-amyloid1-42 (Aβ1-
42), β-amyloid1-40 (Aβ1-40), and pTau181 are valuable...Oct 14, 2022Scientific Poster - Prediction of Amyloid PET Status Using the Lumipulse G β Amyloid Ratio (1-42/1-40)
Background
Cerebrospinal fluid ( amyloid biomarker concentrations are valuable
in the assessment of patients for Alzheimer’s dementia ( Automated...
